Pancreatic Cancer Precision Medicine Market Expected to Surpass USD $1.06 Billion by 2029, Expanding at 16.6% CAGR
Get 20% Off Market Intelligence Reports With Code ONLINE20 – Track Global Tariffs, Economic Shifts, and Sector Transformations
What Is the Growth Potential of the Pancreatic Cancer Precision Medicine Market in the Next Decade?
The pancreatic cancer precision medicine market size has grown rapidly in recent years. It will grow from $0.49 billion in 2024 to $0.58 billion in 2025 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to rise in incidence of pancreatic cancer, growth in understanding of tumor heterogeneity, increase in investment in oncology research, expand in availability of biomarker-driven therapies, improved diagnostic tools for early detection, and rise in adoption of personalized treatment approaches.
The pancreatic cancer precision medicine market size is expected to see rapid growth in the next few years. It will grow to $1.06 billion in 2029 at a compound annual growth rate (CAGR) of 16.6%. The growth in the forecast period can be attributed to growing investments in personalized oncology research, increasing availability of biomarker-based diagnostic tests, rising adoption of targeted therapies, expanding clinical trial pipelines for precision treatments, supportive regulatory initiatives for personalized medicine, and increasing collaborations between biotech companies and research institutions. Major trends in the forecast period include advancements in liquid biopsy technologies, development of personalized immunotherapies, adoption of AI-driven predictive analytics, emergence of novel biomarker discoveries, integration of multi-omics approaches for deeper tumor profiling, and adoption of targeted combination therapies.
Claim your free report sample now:
What Are the Major Drivers Influencing the Pancreatic Cancer Precision Medicine Market?
The rising prevalence of pancreatic cancer is expected to propel the growth of the pancreatic cancer precision medicine market going forward. Pancreatic cancer is a type of cancer that begins in the tissues of the pancreas, an organ essential for digestion and blood sugar regulation. The pancreatic cancer incidence is rising due to the aging population combined with the growing prevalence of risk factors such as obesity, diabetes, and smoking. Pancreatic cancer precision medicine enhances cancer management by offering personalized treatment plans based on genetic and molecular information. It improves treatment effectiveness and reduces side effects, making it a crucial tool in managing pancreatic cancer more efficiently. For instance, in February 2025, according to Cancer Australia, an Australia-based government agency, there were 4,641 new pancreatic cancer cases in 2024, with 2,414 in males and 2,227 in females, marking an increase from 3,968 cases in 2023. Therefore, the rising prevalence of pancreatic cancer is driving the growth of the pancreatic cancer precision medicine market.
Which Segment Holds the Largest Share in the Pancreatic Cancer Precision Medicine Market?
The pancreatic cancer precision medicine market covered in this report is segmented –
1) By Therapeutic Approach: Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations, Other Therapeutic Approache
2) By Diagnostic Technology: Genomic Testing, Molecular Diagnostics, Liquid Biopsy, Biomarker-Based Companion Diagnostics, Other Diagnostic Technologies
3) By Application: Hospitals, Specialty Clinics, Academic And Research Institutes, Diagnostic Centers
Subsegments:
1) By Targeted Therapy: Kinase Inhibitors, PARP Inhibitors, Other Molecular Targeted Agents
2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Therapy, Other Immunotherapy Approaches
3) By Chemotherapy-Precision Combinations: Gemcitabine-Based Combinations, Fluorouracil-Based Combinations, Nab-Paclitaxel-Based Combinations, Other Chemotherapy Combinations
4) By Other Therapeutic Approaches: RNA-Based Therapies, Epigenetic Modulators, Antibody-Drug Conjugates (ADCs), Other Innovative Therapies
What Are the Key Trends Shaping the Pancreatic Cancer Precision Medicine Market?
Major companies operating in the pancreatic cancer precision medicine market are focusing on developing advanced technologies, such as precision medical tool, to enhance early detection, enable accurate tumor profiling, and optimize personalized treatment strategies for improved patient outcomes. A precision medical tool is a specialized device that helps diagnose and treat diseases accurately based on a person’s unique biology. For instance, in January 2024, Cedars-Sinai, a US-based hospital and healthcare company, launched molecular twin precision oncology platform, precision medical tool to better predict pancreatic cancer survival by identifying key biomarkers. The platform's strong potential lies in guiding treatment decisions, even in areas with limited resources, by using blood and tissue samples from 74 patients with pancreatic ductal adenocarcinoma to offer a more accurate and accessible approach to precision oncology.
Which Major Companies Are Operating in the Pancreatic Cancer Precision Medicine Market?
Major companies operating in the pancreatic cancer precision medicine market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Novartis AG, Eli Lilly and Company, Amgen Inc, Teva Pharmaceutical Industries Ltd, Genentech Inc., Illumina Inc., Ipsen Pharma, Guardant Health, FOUNDATION MEDICINE INC., Oncolytics Biotech Inc., Celgene Corporation, Erytech Pharma, PharmaCyte Biotech Inc.
Get the full pancreatic cancer precision medicine market report here:
Which Region Is Expected to Lead the Pancreatic Cancer Precision Medicine Market by 2029?
North America was the largest region in the pancreatic cancer precision medicine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic cancer precision medicine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment